TechnoPhage & PHAXIAM Therapeutics partner to improve phage therapy

TechnoPhage, a Portuguese company specialising in GMP phage development, and PHAXIAM Therapeutics, a biopharmaceutical firm focused on innovative treatments for severe and resistant bacterial infections, announced a strategic collaboration. This partnership aims to provide physicians with access to a comprehensive GMP phage portfolio, facilitating the implementation of Individualised Phage Therapies (IPT) through shared capabilities. The collaboration aims to collect 25 GMP phages by the end of 2025 and 35-40 GMP phages by the end of 2026, significantly enhancing the resources available for combating resistant bacterial infections.

Read here: https://www.bacteriophage.news/technophage-phaxiam-therapeutics-partner-to-advance-ipt-for-drug-resistant-infections/

Unknown's avatar

Published by Dr. Prasanth Manohar, Ph.D.,

Early career researcher in the field of Microbiology. Phage biologist, Author, Editor and Scientific writer. Expertise is in bacteriophage biology & genetics, Phage Therapy, ssRNA phages, Phage lysis systems, Single-cell analysis, protein antibiotics, and Antibiotic Resistance.